Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | FBRX |
---|---|---|
09:32 ET | 178 | 5.63 |
09:45 ET | 300 | 5.78 |
09:52 ET | 820 | 5.295 |
10:55 ET | 100 | 5.591 |
11:00 ET | 134 | 5.6 |
11:06 ET | 738 | 5.6 |
11:08 ET | 400 | 5.59 |
11:20 ET | 200 | 5.51 |
11:22 ET | 3313 | 5.6158 |
11:24 ET | 2100 | 5.53 |
11:26 ET | 1199 | 5.4901 |
02:36 ET | 600 | 5.59 |
02:42 ET | 600 | 5.659896 |
03:54 ET | 213 | 5.6 |
03:57 ET | 1100 | 5.6 |
03:59 ET | 100 | 5.59 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Forte Biosciences Inc | 8.2M | -0.3x | --- |
Nascent Biotech Inc | 8.1M | -3.9x | --- |
Moleculin Biotech Inc | 8.1M | -0.2x | --- |
Carmell Corp | 8.4M | -0.3x | --- |
Burzynski Research Institute Inc | 7.9M | -5.6x | --- |
Cell MedX Corp | 7.6M | -12.4x | --- |
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.00 |
EPS | $-22.03 |
Book Value | $24.30 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.